Beclometasone oral - Soligenix

Drug Profile

Beclometasone oral - Soligenix

Alternative Names: BDP; DOR 201; DOR 202; DOR 203; Oral BDP - Soligenix/Sigma-Tau; Oral beclomethasone 17,21-dipropionate; orBec; OrbeShield; SGX 201; SGX 202; SGX 203

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enteron Pharmaceuticals
  • Developer Fred Hutchinson Cancer Research Center; National Institutes of Health (USA); Soligenix
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Crohn's disease; Acute radiation syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Radiation injuries
  • No development reported Acute radiation syndrome; Crohn's disease
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Crohn's-disease(In adolescents, In children) in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO, Tablet)
  • 08 Dec 2016 Soligenix receives grant from National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA) for beclometasone oral development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top